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Complement activation In experimental IgA nephropathy: An antigen
mediated process. Complement activation associated with immune
complex glomerular deposition plays an important role in renal injury.
In the present studies we performed three series of experiments to
identify how IgA immune complexes activate complement. The first
series of experiments was designed to determine whether the presence
of an antigen within a glomerular IgA immune deposit is required for
complement activation. In these experiments, large-sized covalently
cross-linked IgA oligomers (X-IgA) were prepared with purified IgA
anti-dinitrophenyl (DNP) and a bivalent affinity-labeling antigen, bis-
2,4-DNP-pimelic acid ester. These X-IgA oligomers have free antigen-
binding sites that will bind DNP-conjugated antigens. Two groups of
mice were treated with either X-IgA or X-IgA followed, after two
hours, by an antigen DNP-Ficoll. Immunofluorescent examination of
renal tissues, obtained six hours after the initial injection, revealed an
equal intensity of IgA glomerular deposits in both groups of mice.
Glomerular C3 deposits were only detectable in the renal tissues of mice
that had DNP-Ficoll bound to X-IgA. In the second series of experi-
ments, a pair of preformed IgA immune complexes, differing only in one
antigenic structural feature (DNP), were used to examine the role of the
antigen in inducing glomerular C3 deposits in two groups of mice. These
pre-formed immune complexes were prepared with IgA anti-phosphoryl-
choline (PC) and either PC-conjugated to bovine serum albumin (PC.
BSA) or PC-BSA which was further modified with DNP (PC/DNP-
BSA). Although the IgA immunofluorescent intensity and pattern in the
glomerular deposits were equivalent for both groups, intense C3 depos-
its were exclusively associated with the PC/DNP-BSA-containing im-
mune complexes. Analysis of the relative conversion of normal human
serum C3 to inactive C3b (iC3b) by X-IgA, various antigens and their
respective IgA immune complexes was highly dependent on the nature
of the antigen. Lack of iC3b generation by large-sized IgA aggregates
(X-IgA) was in agreement with the in vivo findings. The results indicate
the nature of the antigen in an IgA immune complex glomerular deposit
represents the major mediator of complement activation.
Glomerular deposits of complement components are consid-
ered important mediators of renal injury [1]. The pathogenetic
evolution of such deposits is usually preceded by glomerular
localization of circulating or in situ formed immune complexes.
Activation of the complement system by IgG and 1gM-containing
immune complexes is initiated by aggregation of the antibodies
[21. A similar capacity of IgA in an immune complex or as an
aggregate remains controversial [3, 4]. Detection of C3 along
with IgA glomerular deposits in patients with primary IgA
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nephropathy has been attributed to the ability of aggregated IgA
to activate the complement alternative pathway [5]. Normal
serum levels of C3 and other complement components reported
for most patients, however, suggest that circulating IgA im-
mune complexes (IgA-IC) in these patients do not activate
complement [6, 71. Tomino and coworkers [8] demonstrated
that glomerular IgA immune deposits are able to activate the
alternative complement pathway of normal human or guinea pig
serum. It is unknown, from these studies, whether the antigen
or the aggregated IgA in the glomerular immune deposits is
responsible for C3 activation.
To discriminate between these two possibilities, we used
covalently crosslinked IgA oligomers to induce glomerular IgA
deposits in an experimental model of IgA nephropathy [91. In
this study we present evidence that the antigen endows the IgA
immune complex with the ability to activate complement.
Methods
Preparation of IgA
Munne plasmacytoma MOPC 315 ascites were collected and
clarified as described [10]. Purification of IgA anti-DNP was
achieved by applying 10 ml of clarified MOPC 315 ascites onto
a 25 ml column of DNP-aminoethylcarboxymethyl-Sepharose
pre-equiliberated with borate-buffered saline (BBS). Bound IgA
was eluted with 67 ml of 0.1 M DNP-OH. The bound hapten
was removed by passing the eluates over a 5-mi Dowex 1-X8
column. The IgA containing eluates were pooled, dialyzed
against BBS, and concentrated by negative pressure in a
collodian sac. The concentration of purified IgA was deter-
mined by absorbance at 280 nm.
IgA anti-phosphorylcholine Was purified from murine plas-
macytoma TEPC 15 ascites as described [11]. Briefly, 10 ml of
clarified ascites was applied onto 25 ml column of phosphoryl-
choline-conjugate of aminoethylcarboxymethyl-Sepharose pre-
equiliberated with BBS. Bound IgA was eluted with 0.1 M of the
hapten phosphorylcholine chloride (PC). Bound PC was re-
moved from the eluted IgA by extensive dialysis against BBS.
Preparation of antigens
The protocol used in preparing aminoethylated carboxy-
methyl-Ficoll has been thoroughly described [12]. A dinitro-
phenyl-Ficoll conjugate was prepared by the method of Inman
[13].
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Synthesis of phosphoryicholine (PC)-carrier conjugates was
performed as described by Rifai and Wong [11]. Briefly, an
isothiocyanate-PC derivative was prepared by mixing p-amino-
phenyl-PC with thiophosgene. The isothiocyanate derivative
was coupled directly to bovine serum albumin (BSA) or amino-
ethylated Ficoll at room temperature in a bicarbonate buffer.
Approximately 20 PC groups per BSA occurred within 40
minutes. The number of PC per carrier was determined spec-
trophotometrically at 245 nm. A part of PC-BSA preparation
was further modified with dinitrofluorobenzene to conjugate
DNP to the PC-BSA. This PC/DNP-BSA antigen was substi-
tuted with approximately 26 DNP molecules, as determined
spectrophotometrically at 360 nm.
Pneumococcal C-polysaccharide antigen was prepared by the
method of Liu and Gotschlich [14].
Radioiodination
Purified IgA was radiolabelled, 200 MCi/mg, with carrier-free
Na 125! (Amersham, chicago, Illinois, USA) by using iodine
monochloride [151.
Preparation of cross-linked IgA oligomers
Purified IgA was cross-linked with the bivalent affinity-
labeling antigen, BDPE, under modified conditions of the
described procedure [16]. In a glass tube, 1.3 mg of BDPE was
dissolved in 0.3 ml of double-distilled dimethyl formamide and
mixed rapidly with 9 ml of IgA (50 mg). The reaction mixture
was incubated in the dark at room temperature for one hour.
Excess ethanolamine (10 d of 16.0 M) was added to terminate
the reaction. The reaction mixture was gel filtered on a 2.6 x
100 cm column of Sephacryl S-300 (Pharmacia, Piscataway,
New Jersey, USA). Large-sized IgA oligomers in the excluded
peak fractions were pooled and concentrated to 7.3 mg/ml.
Animal experiments
Female six-weeks-old BALB/c AnCr1BR mice (Charles
River Breeding Laboratories, Wilmington, Massachusetts,
USA) were used throughout the studies. A single injection of
radiolabelled X-!gA was used to determine the clearance kinet-
ics and optimal conditions for glomerular deposition [101.
The experimental groups used for studies of glomerular
deposition of IgA and C3 were treated with: (1) large-sized
X-IgA only; (2) X-IgA followed by the injection of DNP-Ficoll
at four hours; (3) soluble immune complexes containing IgA
anti-DNP and DNP-Ficoll; (4) soluble complexes containing
IgA anti-PC and PC-BSA; and (5) soluble complexes containing
IgA anti-PC and PC/DNP-BSA. Control mice received an
equivalent dose of either IgA or the antigen alone. At the six
hour period all the mice were sacrificed.
Immunofluorescent evaluation
A portion of the mouse renal cortex was snap-frozen in OCT
(Ames), and cut with a cryostat into 4 sm sections. The
sections were air dried, fixed in acetone for 10 minutes at room
temperature and washed with phosphate buffered saline (PBS)
prior to incubation with fluorescein-labeled antiserum. Anti-
sera, diluted 1:20, used were goat anti-mouse IgA (Meloy
Laboratories) and goat anti-mouse C3 (Cooper Biomedical).
Slides were incubated for 30 minutes at 37°C in a humid
chamber washed with PBS, counterstained with Evans Blue
diluted in PBS, and mounted with PBS-buffered glycerol.
Activation of serum C3
Activation of normal human serum C3, by various antigens
and immune complexes, was assayed by quantitation of iC3b
[171. In this assay fresh, normal human serum (100 d) was
mixed with an equal volume of the appropriate test material: (1)
purified IgA anti-DNP (100 pg); (2) X-IgA (100 pjg); (3) IgA
anti-PC (100 pg); (4) pneumococcal C-polysaccharide (100 pg);
(5) complexes of pneumococcal C-polysaccharide (100 tg) and
IgA anti-PC (100 /Lg); (6) PC-Ficoll (1 mg); (7) complexes of
PC-Ficoll (1 mg) and IgA anti-PC (100 pg); (8) PC-BSA (1 mg);
(9) complexes of PC-BSA (1 mg) and IgA anti-PC (100 jsg); (10)
PC/DNP-BSA (1 mg); and (11) complexes of PCIDNP-BSA (1
mg) and IgA anti-PC (100 /Lg). The reaction mixture was
incubated at 37°C for 30 minutes followed by immediate immer-
sion in iced water bath.
Quantitation of iC3b in the serum samples was determined by
a monoclonal immunoassay (Cytotech, San Diego, California,
USA). Briefly, this assay consisted of three steps. In the first
step, standards, controls, and test specimens were added to
microassay wells pre-coated with anti-iC3b monoclonal anti-
body. This monoclonal antibody is specific for iC3b and will not
bind C3, C3b nor any smaller C3b degradation fragments. Mter
incubation, a wash cycle removed unbound material. In the
second step, horseradish peroxidase-conjugated, goat anti-
human iC3b was added to each test well. After incubation, a
wash cycle removed unbound, excess conjugate. In the third
step, a chromogenic enzyme substrate was added to each
microassay well. After incubation for 20 minutes the enzyme
reaction was stopped and the color intensity was measured
spectrophotometrically at 405 nm. The color intensity of the
reaction mixture was proportional to the concentration of iC3b
present in the test specimens, standards, and controls.
Results
Properties of the cross-linked IgA oligomers
The bivalent affinity-labeling antigen, bis-2,4-dinitrophenyl
(DNP) pimelic ester (BDPE) was used to cross-link specifically
purified IgA anti-DNP obtained from murine myeloma (MOPC
315). The formation of covalently cross-linked oligomers, as
described by Plotz et al [16], is illustrated in Figure 1. In this
reaction the antigen cross-links the specific antibody as follows:
(1) the DNP group acts as antigenic determinant; (2) the
adjacent ester bond is activated; (3) the free hapten DNP-OH is
liberated; and (4) a covalent bond is formed between the
dicarboxylic acid and the amino groups in or near the antigen
combining site.
Large-sized oligomers (X-IgA), which represented 38% of the
total IgA, were separated by gel filtration from the unreacted
IgA and the small-sized oligomers in the reaction mixture. The
molecular weight of the X-IgA, eluted between 36 and 43% of
the column volume, was greater than 1.2 x 106 daltons.
Spectrophotometric analysis, at 360 nm, of the extensively
dialyzed and concentrated eluates confirmed the absence of any
DNP hapten in the purified oligomers. It is of interest to note
that such purified oligomers, in addition to being large-sized
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Fig. 1. Diagram schematizes the formation of covalently cross-linked oligomers with bivalent affinity labeling antigen. Bis-2,4-dinitrophenyl
pimelic acid ester (BDPE) binds specifically to the anti-dinitrophenyl antigen-combining site (Anti-DNP) in the first phase of the reaction.
Covalently cross-linked oligomers (X-Anti-DNP) are formed, in the second phase, as a result of an amidate bond between the carboxyl group on
the pimeiic acid and an amino group on the anti-DNP. During the second phase the hapten, DNP-OH, is released.
aggregates of IgA, will bind DNP-containing antigens more
avidly than the original purified IgA.
Glomerular deposition of IgA
Preliminary experiments were conducted to determine the
minimal amount of large-sized X-IgA required for glomerular
deposition. Increasing doses (0.1, 0.5, 1.0, 1.5, and 2.0 mg) of
X-IgA were administered intravenously to mice in groups of
three that were sacrificed at 1, 6, 12, and 24 hours after
injection. Glomerular IgA deposits could only be detected in
renal tissues obtained one hour after injecting 2 mg of X-IgA. At
this dose, the X-IgA were eliminated from the circulation with
a half-life equal to 5.2 minutes. In contrast, only 1 mg of IgA
complexes prepared with DNP-Ficoll was required for glomer-
ular deposition and persisted in the renal tissues up to 72 hours.
Glomerular deposition of C3
To maximize the glomerular deposition and persistence of
X-IgA, a 3 mg amount was administered in four equal doses
over a period of two hours; the mice were sacrificed four hours
after injection. Immunofluorescent microscopy demonstrated
the localization of IgA and the absence of C3 in the area of the
glomerular mesangium (Fig. 2A, B). The IgA pattern consisted
of global-generalized deposits. As expected these X-IgA depos-
its lacked any DNP, as determined by indirect immunofluores-
cent staining using rabbit anti-DNP as the primary antibody.
The influence of the antigen on glomerular deposition of C3
was examined in a group of three mice that received X-IgA (3
mg), as above, and followed by the administration of DNP-
Ficoll (5 mg), two hours later. Thus, the antigen was injected
after the disappearance of X-IgA from the circulation. The mice
were sacrificed two hours after the administration of the anti-
gen. Immunofluorescent staining was positive for IgA and C3
with the characteristic global-generalized pattern shown in
Figure 2C, D. The presence of the DNP-Ficoll in these com-
plexes was confirmed by indirect immunofluorescent staining
with rabbit anti-DNP.
Mice that received immune complexes prepared with IgA (3
mg) and DNP-Ficoll (18 mg) were sacrificed six hours alter
injection. Immunofluorescent examination revealed a typical
global-generalized diffuse granular pattern of IgA and C3 (Fig.
2E, F).
Control mice that received a similar dose of IgA or DNP-
Ficoll alone did not show any glomerular deposition of either
IgA, C3, or the antigen.
Intensity of the immunofluorescent staining for IgA and C3
was evaluated for all the experimental or control groups (Fig.
3). A grade of 0 to 3 + was assigned to the staining intensity of
each glomerular cross-section that was examined. Although a
similar percentage of glomerular cross-sections with an IgA-
staining intensity of 1 to 2+ were noted in mice that received
X-IgA (60%) or X-IgA followed by the antigen (72%), only the
mice in the latter group demonstrated C3 deposits in their
glomeruli (45%). This suggests that the antigen binding to the
deposited X-IgA resulted in complement activation.
The importance of the nature of the antigen in activating C3
was also examined by comparing two similar types of IgA
immune complexes. Purified IgA antiphoshoryicholine (PC),
obtained from TEPC 15 plasmacytoma, was mixed with an
antigen, prepared either as PC-conjugated to bovine serum
albumin (PC-BSA) or PC-BSA that has been further modified
with DNP (PCIDNP-BSA). Thus, the two antigens contained an
identical number of PC but differed in the DNP content. The
two types of preformed IgA immune complexes, 1.7 mg of IgA
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Fig. 2. Immunofluorescence micrographs representative of IgA and C3 deposits in glomeruli of mice that received either X-IgA (A and B), X-IgA
followed by DNP-Ficoll (C and D), or a mixture of IgA anti-DNP and DNP-Ficoll complexes (E and F). Non-specific staining of the tubular
basement membrane and Bowman's capsule with the anti-mouse C3 was noted in all the experimental and control specimens.
and 5.2 mg of either PC-BSA or PC/DNP-BSA, were adminis- C3 deposits in a global-generalized pattern. In contrast, mice
tered intravenously into two groups of mice that were sacrificed that received PC-BSA and IgA complexes showed no glomer-
six hours alter injection. Immunofluorescent examination of the ular C3 deposits. Control mice that received an equivalent dose
renal tissues revealed an identical pattern of IgA deposits in of either antigen also showed no C3 deposits. These results
both groups of animals. The group that received complexes demonstrate that the composition of the antigen, DNP-conjuga-
containing PC/DNP-BSA showed a strong (2 to 3+) intensity of ted to a protein carrier, plays a critical and exclusive role in
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Fig. 3. Glomerular distribution of IgA (solid bars) and C3 (striped
bars) in mice that received either X-JgA, X-IgA followed by DNP-
Ficoll, or a mixture of IgA and DNP-Ficoll represented on the Y axis.
Approximately 150 glomerular cross-sections were evaluated for im-
munofluorescent intensity (X axis) and distribution (Z axis).
complement activation by the glomerular IgA immune deposits.
Also these results ruled out the possibility that the process of in
situ complex formation, observed by the DNP-Ficoll binding to
the glomerular deposits of X-IgA, may have activated C3.
Activation of serum C3
The ability of X-IgA, IgA immune complexes and various
antigens to activate normal human serum-C3 was also investi-
gated. In this assay fresh, normal human serum (100 d) was
mixed with a 100 g of either unreacted IgA (control), X-IgA, or
IgA immune complexes prepared with anti-PC and a specific
PC-containing antigen. The antigen consisted of either pneumo-
coccal C-polysaccharide (100 pg), PC-BSA (1 mg), or PC/DNP-
BSA (1 mg). The reaction mixture was incubated at 370 C for 30
minutes and followed immediately by immersion in an iced
water bath. An enzyme immunoassay was used for quantitating
C3 cleavage product (iC3b) in the treated serum.
The levels of iC3b in the serum samples treated with different
preparations are illustrated in Figure 4. There was no significant
difference between the unreacted IgA anti-DNP (sample B, 13
g) and the X-IgA (sample C, 17.8 jig). In contrast, treatment of
the serum only with the pneumococcal C-polysaccharide (sam-
ple E), PC-BSA (sample G) or PC/DNP-BSA (sample I),
resulted in elevated levels of iC3b (59, 110, and 170 g,
respectively). Complexes prepared with IgA anti-PC and either
the C-polysaccharide (sample F), PC-BSA (sample H), or
PCIDNP-BSA (sample J) resulted also in elevated levels of iC3b
Fig. 4. Quantitation of iC3b in serum treated with IgA, antigens, and
the respective immune complexes. Serum samples were treated as
follows: (A) none; (B) IgA anti-DNP; (C) X-IgA; (D) IgA anti-PC; (F)
pneumococcal C-polysaccharide; (F) pneumococcal C-polysaccharide
÷ IgA anti-PC; (G) PC-BSA; (H) PC-BSA + IgA anti-PC; (I) PCIDNP-
BSA; (J) PCIDNP-BSA + anti-PC.
(80, 130, and 220 g, respectively). The antigen PC-Ficoll and
the IgA complexes prepared with it, however, failed to generate
any significant levels of iC3b (data not shown). These results
support the in vivo findings by demonstrating that the nature of
the antigen plays the critical role in activation of C3.
Discussion
A murine experimental model of IgA nephropathy was used
to investigate complement activation by IgA immune com-
plexes. In this model the presented data permit a conclusion
that the antigen component of the glomerular IgA immune
deposits is responsible for the activation and co-deposition of
C3. First, glomerular deposits that contained exclusively IgA
aggregates failed to show any C3 deposits. Second, only the
presence of a complement-activating antigen in the immune
deposits induced C3 glomerular deposition. Third, in vitro
studies demonstrated that generation of iC3b in normal serum
treated with IgA immune complexes was a function of the
antigen.
The utilization of the affinity-labeling bivalent hapten, BDPE,
offered a unique advantage for preparing IgA oligomers that
mimick antigen-antibody complexes in that the attachment
occurs at the antibody binding site. Unlike other complexes,
however, the attachment is covalent, Thus, the IgA molecules
within such a complex are maintained in a stable array with a
natural spatial orientation. The irreversible binding also allowed
us to purify stable, large-sized IgA oligomers that do not
250
A B C D E F G I-I I J0
Complement in igA nephropathy 843
rearrange into a smaller size. Another advantage of such
oligomers is the dissociation of the DNP hapten in the antigen
binding site prior to the covalent cross-linkage of the specific
IgA molecules. Accordingly, there were no DNP molecules
within the purified aggregate that would have induced or
contributed to complement activation.
The importance of the size of IgA immune complexes in
glomerular deposition was addressed in previous studies [18]. It
was demonstrated that large or intermediate-sized complexes
were required for glomerular deposition. In small doses, large-
sized IgA immune complexes are rapidly (half-life < 2 mm)
eliminated from the circulation by specific hepatic receptors
[19]. Saturation of these receptors with a relatively large dose of
X-IgA, 3 mg, prolongs the half-life of these oligomers in the
circulation and enhance their chance of renal deposition. These
observations are similar to the ones reported for the passive
model of glomerular IgG immune complex deposition, where a
large dose, 5 mg, of IgG immune complexes is required for the
saturation of the mononuclear phagocytes system [20].
It is well established that large clusters of IgG molecules
initiate complement activation more efficiently than small-sized
aggregates [21]. Despite the selection of exclusively large-sized
IgA oligomers in our studies, to favor an opportunity for
maximal efficiency of complement activation, the X-IgA failed
to activate C3 in vivo (Fig. 2B) or in vitro (Fig. 4). In contrast,
binding of the DNP-Ficoll to the immobilized deposits of X-IgA
in the glomerular tissues resulted in activation of C3 (Fig. 2D).
Based on our previous studies of the X-IgA clearance kinetics
[10] and in order to avoid the potential formation of insoluble
complexes in the circulation, the DNP-Ficoll was administered
after the disappearance of X-IgA from the circulation. This
experimental protocol also insured that an equivalent number of
X-IgA would have deposited in the glomeruli of mice that
received either X-IgA alone or X-IgA with the subsequent
DNP-Ficoll administration. The similarity of the IgA im-
munofluorescent intensity in the glomeruli of these two groups
(Fig. 3) supports this conclusion. It was possible, however, that
the process of DNP-Ficoll binding in situ to the X-IgA may have
activated complement. Such a possibility was eliminated by the
paired comparison of similar-sized preformed IgA immune
complexes. In these experiments the same IgA, anti-PC, was
used in preparation of complexes with either PC-BSA or
PCIDNP-BSA. Both antigens have an identical number of the
antibody-binding PC determinants that would insure an identi-
cal interaction with the IgA, but different DNP content. Al-
though both types of immune complexes resulted in intense IgA
glomerular deposits, only the DNP-containing complexes in-
duced concomitant glomerular C3 deposits.
The ability of DNP-conjugates to activate the alternative
pathway was described by Konig et a! [221. They demonstrated
a correlation between the extent (50%) of C3 activation in
normal guinea pig serum and the increasing density of DNP
substitution on the carrier molecule, human serum albumin
(HSA). Albumin substituted with 56 to 60 DNP molecules was
optimally active at a concentration of I mg/mi. A lower substi-
tution of 32 to 36 DNP/HSA had its optimum at 5 mg/ml and the
least efficient was 15 to 19 DNP/HSA that required a large
concentration, 20 mg/mi. In agreement with this report, we
confirmed the ability of DNP-conjugated albumin to activate C3
(sample in Fig. 4). In addition, we discovered that BSA substi-
tuted with a phenyl-derivative of PC (isothiocyanophenyl-
phosphorylcholine) was also efficient in activating C3 in normal
serum (sample G in Fig. 4). Lack of C3 activation by the
glomerular deposits of IgA-PC-BSA could be due to the mask-
ing of the phenylated-PC on the BSA with IgA anti-PC or due to
the interaction of positively charged PC with a mesangial
component. In contrast, the IgA-PCIDNP-BSA glomerular de-
posits were efficient in C3 activation due to the exposed DNP,
a hydrophobic moiety, on the antigen. In addition our data
suggest that the presence of a DNP or a phenylated hapten on
the antigen is a necessary but not a sufficient requirement for
efficient complement activation. Administration of a large dose
of DNP-Ficoll (18 mg) and IgA (3 mg) resulted only in a slight
increased immunofluorescent intensity (1 to 2+) of C3 in only
10% of the glomerular cross-sections (Fig. 3). It is of interest
that DNP-Ficoll or the soluble IgA-DNP-Ficoll complexes were
inefficient activators of normal human serum C3. Together
these observations suggest that the nature of the carrier mole-
cule plays a critical role in complement activation. Thus, the
carbohydrate polymer Ficoll was inefficient in comparison with
the protein albumin.
Activation of the alternative pathway by antigens indepen-
dent of any antibody involvement was first described by Pillmer
et al [23]. They demonstrated that a variety of microbial
antigens, such as bacterial cell walls, toxins, and polysaccba-
rides were efficient activators of the properdin system. In this
study we examined the ability of the Pneumococcal C-polysa-
ccharide to activate normal human serum C3 (Fig. 4). This
antigen is naturally substituted with a high density of phospho-
rylcholine [24]. At a low concentration (100 g/ml) it generated
60 pg/ml of iC3b. Recently, we demonstrated that mice treated
with a low dose (50 g) of this antigen and IgA anti-PC (1.0 mg)
developed glomeruionephritis with intense C3 deposits [25].
Thus, naturally occurring bacterial antigens complexed with
IgA are capable of mediating complement activation. An insol-
uble complex of C-polysaccharide (100 g) and IgA anti-PC
(100 g) enhanced slightly the iC3b level (80 g/ml). This level
is not significantly different from the expected additive effect of
a mixture of antigen (60 g/ml) and IgA (10 jg/ml). This
observation is also applicable to the IgA-PC-BSA compJexes
(sample H, Fig. 4). In contrast the preformed IgA-PC/DNP-
BSA complexes were effective in generating iC3b than the
antigen-antibody serum mixture (sample J, Fig. 4). The role of
antibody enhancement of the alternative pathway activation
was first demonstrated with the guinea pig antibody specific for
DNP [26]. In this system the enhancement was demonstrated to
be independent of the immunoglobulin Fc fragment [27]. Thus,
the antibody enhancement of the alternative pathway activation
by an antigen is due to an aggregating effect.
An important point needs to be considered in view of the
presented data. Evidence for activation of C3 by aggregated
IgA is based on in vitro studies that utilized different manipu-
lations, such as treatment with azobenzedine diamine or inter-
facial aggregation, to induce an IgA precipitate [4, 5]. In those
experiments and in others it was demonstrated that chemical
modification or unfolding of hydrophobic portions of the Fab
and not the Fc portion of IgA resulted in C3 activation [4].
Under the more physiological conditions, however, human IgA
with specificity for blood group A failed to induce hemolysis or
C3 activation (3). Studies using murine IgA with specificity for
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DNP- or PC-conjugated antigens showed only cleavage but no
fixation of C3 in normal guinea pig or mouse serum [28, 29]. It
is noteworthy that in those experiments the possibility of C3
cleavage by the DNP or the azophenylphosphorylcholine on the
antigen in the insoluble-IgA immune complexes was not exam-
ined. Our results support such a possibility.
In experimental IgA nephropathy induced by oral immuniza-
tion there was no C3 deposits despite intense IgA immune
deposits [303. In contrast, in the experimental model of sys-
temic immunization with neutral or charged dextran, mice that
received dextran sulfate, a well-known activator of the alterna-
tive pathway, showed C3 deposits along with IgA [311. Clini-
cally, two separate studies evaluated the correlation between
C3, IgA and other immunoglobulins in the renal biopsies of 525
patients with IgA nepbropathy [32, 331. Both studies demon-
strated that only 55%of the patients had C3 glomerular deposits
when IgA was the exclusively deposited immunoglobulin. In
contrast, 85 to 90% of the patients had C3 deposits when IgG
and/or 1gM was codeposited with the IgA. It is also well
established that serum levels of different complement compo-
nents are normal in patients with IgA nephropathy [6, 73.
Collectively, these experimental and clinical studies support
our suggestion that the antigen or other classes of immunoglob-
ulins codeposited with the IgA in the glomerular immune
deposits mediate complement activation.
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